Back to today’s briefing

Story perspectives

New GLP-1 Drug Targets Feline Obesity Crisis

1/10/2026

50 10

Summary

Story summary

Okava Pharmaceuticals, a San Francisco-based company, has launched a pilot study of MEOW-1, a GLP-1 drug for feline obesity.
The treatment uses small injectable implants releasing medication up to six months.
About 60% of U.S. pets are obese, highlighting potential demand.
Costs may be prohibitive; experts say it should complement traditional weight management.

1 of 1

Story summary

Okava Pharmaceuticals, a San Francisco-based company, has launched a pilot study of MEOW-1, a GLP-1 drug for feline obesity.
The treatment uses small injectable implants releasing medication up to six months.
About 60% of U.S. pets are obese, highlighting potential demand.
Costs may be prohibitive; experts say it should complement traditional weight management.